Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: Efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Weinblatt, Michael E ^a   Fleischmann, Roy ^b   van Vollenhoven, Ronald F ^c   Emery, Paul ^d,e   Huizinga, Tom WJ ^f   Cutolo, Maurizio ^g   van der Heijde, Désirée ^f   Duncan, Benjamin ^h   Davies, Owen ^h   Luijtens, Kristel ^h   Dougados, Maxime ^i,j  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF GENOA   (Italy)

^h UCB PHARMA   (Belgium)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j Cochin Hospital ^*  (France)

more..

Author keywords

Anti TNF; DMARDs (biologic); Rheumatoid arthritis

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; AUTACOID;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DAS28; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINUSITIS; SKIN DISEASE; SUBCUTANEOUS FAT DISORDER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CERTOLIZUMAB PEGOL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NASOPHARYNGITIS; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84946829699     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0841-9     Document Type: Article

References (25)

1. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol. 2003;30:1138-46.
2. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789-96.
3. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
4. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-81.
5. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602.
6. Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford). 2012;51:2204-14.
7. van der Heijde D, Keystone EC, Curtis JR, Landewe RB, Schiff MH, Khanna D, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol. 2012;39:1326-33.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
9. US Food and Drug Administration. Reporting serious problems to the FDA: what is a serious adverse event? 2014. Available at: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm. Accessed 10 November 2015.
10. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68:805-11.
11. Keystone E, Heijde D, Mason Jr D, Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319-29.
12. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68:797-804.
13. Schiff M, Davies OR, Bennett B, Luijtens K, Furst DE. Certolizumab pegol plus methotrexate is similarly effective in active rheumatoid arthritis regardless of prior tnf inhibitor use: analysis of the DOSEFLEX phase IIIb study. Ann Rheum Dis. 2012; Suppl 3:665.
14. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806.
15. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-23.
16. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-23.
17. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210-21.
18. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007;66:302-7.
19. Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum. 2008;59:32-41.
20. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:69-74.
21. Klaasen R, Cantaert T, Wijbrandts CA, Teitsma C, Gerlag DM, Out TA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology (Oxford). 2011;50:1487-93.
22. Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis. 2013;72:3-6.
23. Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol. 2006;33:659-64.
24. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508-16.
25. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.